Commercial Insight: Hiv - The Battle For Market Share Is Getting Fiercer

By Author: Manjula Menon
Total Articles: 1477
Comment this article

In 2007, HIV drugs achieved sales of $9.3 billion in the 7MM, growing faster than the overall market at a CAGR of 11.3% from 2004-2007. Due to patent expirations, Datamonitor expects the market's growth to slow down somewhat, reaching total sales of $15.1 billion in 2017. Among the ROW, the Canadian HIV market in 2007 was worth $272 million, achieving a CAGR of 24% from 2004-2007.

Scope of this report

In-depth analysis of the current HIV market across the US, EU, Japan and a ROW snapshot

Thorough assessment of underlying commercial and clinical factors shaping the antiretroviral market

Detailed sales forecasts for the major antiretroviral classes, molecules and brands in each of the seven major markets

Case study analysis of the Canadian market including an in-depth assessment of the healthcare system and potential opportunities and threats

Research and analysis highlights

Gilead is now the market leader in HIV with a portfolio of just four marketed products. Datamonitor expects JnJ/Tibotec and Merck to be the fastest growing companies over the next 10 years. While Tibotec ...
... only entered the field with the launch of its first product in 2006, Merck & Co.'s first-in-class Isentress reenergized its HIV efforts in 2007.

The HIV market is very concentrated, with the top 10 brands accounting for 80% of total antiretroviral sales across the 7MM in 2007. Truvada was the bestselling drug with revenues of $1.5 billion. Gilead and BMS' rapidly growing joint venture Atripla was already the fourth best selling HIV drug despite the absence of ex-US sales during the period.

While the 7MM and Canada are commercially the most significant for HIV, companies are now turning towards fast-growing emerging markets as new sources of revenue growth. The potential is there: the 7MM only account for 36% of the globally infected population, but more than 85% of revenues.

Key reasons to read this report

Understand the changing market dynamics of HIV drugs, key success factors for leading brands as well as the impact of pending patent expiries

Understand the patient acquisition process with key inflection points in the decision-making process to choose antiretroviral drug brands

Obtain full global, country, class and product-specific forecasts of currently marketed and pipeline antiretrovirals from 2007 to 2017

For more information Kindly visit the website : http://www.bharatbook.com/detail.asp?id=82016

Or Contact us on :
Tel No : (+9122 )27578668 , 27579438
Fax: (+9122 )27579131

Address :
Bharat Book Bureau,
207,Hermes Atrium,
Sector-11
P.O Box 54,
CBD Belapur,
Navi Mumbai - 400614.

Bharat BooK Bureau is the leading market research information aggregator which provides reports, Company profiles, newletters, country info. and online databases for the past twenty years to corportate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies. It helps global companies to know different market before starting up business / expanding in different countries across the world. www.bharatbook.com is one stop shop for the business intelligence information requirements.